DE-RUI HUANGCHIH-HSIN YANG2024-03-132024-03-132024-02-1215356108https://scholars.lib.ntu.edu.tw/handle/123456789/640815Immune checkpoint inhibitors have reshaped the treatment landscape of non-small cell lung cancer (NSCLC). However, chemoimmunotherapy trials dedicated to squamous NSCLC are limited. In this issue of Cancer Cell, Zhou et al. demonstrate serplulimab plus chemotherapy as an effective first-line regimen to treat patients with advanced squamous NSCLC.en[SDGs]SDG3journal article10.1016/j.ccell.2024.01.004383504192-s2.0-85183970832https://api.elsevier.com/content/abstract/scopus_id/85183970832